The current results suggested the specificity of VHLα exerting anti-tumoral function against activated hnRNPA2B1 in renal tumors, and therefore somatic mutations in VHLα which interrupted the feedback loop might compromise its tumor suppressor activity, which worthied further investigations to fully understand the novel isoform of VHL. The gene discussed is HNRNPA2B1; the disease is neoplasm.